Biocytogen 

Preclinical Services

>The mouse model and efficacy evaluation of immunological checkpoint

Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy. Major pharmaceutical companies in the world have devoted great effort to develop cancer immunity-related treatment methods. Results from clinical trials showed that the treatment efficacy is very high. Thus, Science magazine ranked cancer immunotherapy to be first place among the top ten scientific breakthroughs in 2013.


Human PD-1 (KeytrudamAb efficacy evaluation (MC38 Cell line)


 1532684883907023.jpg

 

Fig.1 MC38 Cell line were subcutaneously implanted into homozygous B-hPD-1 mice. Mice were grouped when the tumor size was 150±50 mm3 (n=5). The high dose, mid dose and low dose of human PD-1 antibody Keytruda all significantly inhibited tumor growth, confirming that the B-hPD-1 mouse model is a powerful tool for in vivo PD-1 antibody pharmacological efficacy studies. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


Human PD-1 (Keytruda) mAb efficacy evaluation (MC38 Cell line)


1533293801103405.png


Fig.2 EL-4 Cell line were subcutaneously implanted into homozygous B-hPD-1mice. Mice were grouped when the tumor size was 150±50 mm3 (n=5). Different doses of human PD-1 antibody Keytruda all obviously inhibited tumor growth, confirming that the B-hPD-1 mouse model is a powerful tool for in vivo PD-1 antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

Human PD-L1 (Tecentriq) mAb efficacy evaluation (MC38-hPD-L1 Cell line)


1533293844119972.png

Fig.3 Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1 mice. Mice were grouped when the tumor size was approximately 100 mm3 (n=7). The human PD-L1 antibody Tecentriq significantly inhibited tumor growth, confirming that the B-hPD-1 mouse model is a powerful tool for in vivo PD-L1 antibody pharmacological efficacy studies. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


Combination therapy of PD-1 (Keytruda) mAb/PD-L1 (Tecentriq) mAb and chemo therapy drugs


Combination therapy of PD-1 (Keytruda) mAb and chemotherapy drugs (MC38-hPD-L1 cell line)


1533293894413578.png

 

Fig.4 Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=8). The combination of anti-hPD-1 antibody Keytruda and the chemotherapy drug Cisplatin shows more inhibitory effects than individual groups, suggesting that B-hPD-1 mouse model is a powerful tool for evaluating combination therapies in vivo. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.


Combination therapy of PD-L1 (Tecentriq) mAb and chemotherapy drugs (MC38-hPD-L1 cell)


1533293959520469.png

 Fig.5 Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1 mice. Mice were grouped when the tumor size was approximately 100 mm3 (n=7). The combination of anti-hPD-L1 antibody Tecentriq and the chemotherapy drug Cisplatin shows more inhibitory effects than individual groups, suggesting that B-hPD-1 mouse model is a powerful tool for evaluating combination therapies in vivo. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

 

【Return list】
* Contact Name
* Quantity
Telephone No.
Email
* Shipping address
Verification code captcha

© 2018 Beijing Biocytogen Co., Ltd. All rights reserved. Technical support: fast help cloud